Beta Drugs Ltd (BETA)

📊 Quarterly Results (₹ Cr)

Revenue has grown sequentially and YoY, rising from ₹87 crores in Dec 2025 to ₹126 crores in Jun 2026, with operating profit and margins improving consistently — OPM reached 18.3% in Jun 2026 from 13.7% in Mar 2026. Net profit and EPS have risen in tandem, reflecting operational efficiency and margin expansion. This growth is underpinned by strategic moves such as the Nivian Lifesciences acquisition, which targets INR45-46 crores in IVF revenue with 18-19% EBITDA margin, and the shift toward higher-margin branded and export segments. Management expects export revenue to grow over 50% in FY27 and reach INR200-250 crores by FY28, contributing to a projected FY27 revenue of INR530 crores and 24% EBITDA margin.

🔮 Management Outlook & What's Next

Management reaffirmed its FY27 guidance of INR530 crores revenue and 24% EBITDA margin, with a long-term target of INR900 crores revenue by 2030 and 20-25% annual growth across core segments. They emphasized a strategic shift toward high-margin businesses, aiming for >80% turnover from such segments by 2030. Key initiatives include capacity expansion (lyophilization lines, KSM plant), regulatory compliance (PIC/S audit clearance), and new product launches (Megestrol, Methotrexate, Imatinib). Export growth is expected to accelerate, with a 30% YoY increase in H1 FY27 and a target of INR200-250 crores by FY28. Management also expects Derma EBITDA to remain positive and IVF business to double with 4.5% market share in a INR3800 crore market.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet shows a stable capital structure with total assets growing from ₹436 crores in Mar 2025 to ₹496 crores in Mar 2026, driven by rising reserves and controlled borrowing increases from ₹133 to ₹148 crores. Equity remains constant at ₹10 crores, but reserves have grown from ₹187 to ₹235 crores, indicating retained earnings are being reinvested. Borrowings are modest and declining on a net basis post-conversion of debentures, with interest expenses minimal. The company utilized 100% of the ₹117.01 crores raised via preferential issue, with no deviation in fund allocation, signaling disciplined capital deployment toward acquisitions, capacity expansion, and working capital without over-leveraging.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Promoter holding has declined from 66.73% in Q4FY26 to 59.1% in Q1FY27, while FII and DII holdings have increased slightly, from 0.9% and 0.29% to 1.02% and 6.23% respectively. The number of public shareholders has grown from 3,184 to 7,359, suggesting rising retail and institutional interest. This diversification may reflect improving investor confidence and broader market participation, though the decline in promoter stake could signal ongoing stake sales or dilution from strategic initiatives. The increase in institutional participation is modest but notable given the small base.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Export revenue remains volatile due to dependence on a few countries (30% from five nations) and exposure to missed tenders, with INR20-25 crores potentially lost in FY26 due to tender setbacks. 2. CDMO segment growth has plateaued, with its share expected to fall from 39% to 13% by FY30, requiring successful transition to branded and high-margin products. 3. Capacity utilization is currently only 40-45% in oral solids, meaning significant capex is needed to scale up and achieve target revenue of INR900 crores by 2030 without over-leveraging. 4. Raw material inflation, though partially mitigated by a 5-month inventory buffer, remains a macro risk that could pressure margins if not fully passed on.

📋 Recent Filings

• 🟡 Board Meeting2026-08-18Beta Drugs Limited announced the board approved the allotment of 35,383 bonus equity shares to CCD holders, effective 18 August 2026, following a brie…
• Announcement2026-07-27Beta Drugs Limited presented its FY26 investor deck highlighting robust growth across oncology, IVF, and dermatology segments. Revenue reached INR 3,8…
• Announcement2026-07-23Beta Drugs Limited issued revised Limited Review Reports with UDIN to correct an oversight in its standalone and consolidated financial results filing…
• Financial Results2026-07-22No summary available
• 🟡 deviation variation2026-07-20Beta Drugs Limited confirmed no deviation in the use of funds from its November 2024 preferential issue, with all allocations matching original plans …
• 🟡 Board Meeting2026-07-20Beta Drugs Limited announced its Q1FY27 results on 20 July 2026, reporting consolidated revenue of ₹127.13 crores, up 25.3% YoY, with consolidated net…
• Announcement2026-06-15Beta Drugs Limited clarified that recent price and volume movements in its shares are purely market-driven with no undisclosed price-sensitive informa…
• Announcement2026-06-12No summary available
• 🔴 Financial Results2026-05-22{ "summary": "Beta Drugs Limited reported FY26 revenue of INR396 crores, up from INR368 crores, with EBITDA margin expanding to 22.57% from 21.1%. B…
• Announcement2026-05-15No summary available

🧠 Analyst's Read

Beta Drugs is executing a clear transformation toward higher-margin, export-driven growth, supported by solid operational performance, margin expansion, and strategic acquisitions. The near-term outlook is positive with strong top-line growth and improving profitability, but execution risks remain around scaling capacity, managing export concentration, and converting CDMO infrastructure into sustainable branded revenue. Investors should monitor quarterly export trends, progress on capacity utilization, and timely delivery of new product launches and regulatory milestones.

Based on filing content and financial data. Not a recommendation.